IP Library Granted Patent US 8,603,778
Granted Patent B2
US 8,603,778 · App. 13/547,557 · Granted Dec 10, 2013

Anti-TNF antibodies, compositions, methods and uses

Inventors: George Heavner (Malvern, PA); David M. Knight (Berwyn, PA); Jill Giles-Komar (Downingtown, PA); Bernard Scallon (Collegeville, PA); David Shealy (Downingtown, PA)
Assignee: Janssen Biotech, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,603,778
App. No.
13/547,557
Granted
Dec 10, 2013
Kind
B2
Abstract

The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.

Claims (5)

1. An isolated nucleic acid encoding an isolated mammalian anti-TNF antibody having a variable region comprising SEQ ID NO: 7 or 8.

2. An isolated nucleic acid vector comprising an isolated nucleic acid according to claim 1 .

3. A prokaryotic or eukaryotic host cell comprising an isolated nucleic acid according to claim 2 .

4. A host cell according to claim 3 , wherein said host cell is a selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

5. A method for producing a anti-TNF antibody, comprising translating a nucleic acid according to claim 1 under conditions in vitro, in vivo or in situ, such that the TNF antibody is expressed in detectable or recoverable amounts.

Assignments (2)
MERGER Recorded Oct 3, 2013
From: CENTOCOR, INC.
To: CENTOCOR ORTHO BIOTECH INC.
Reel/Frame 031337/0037 →
CHANGE OF NAME Recorded Oct 3, 2013
From: CENTOCOR ORTHO BIOTECH INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 031337/0196 →
Continuity (6)
Continuation 12271120 · Nov 14, 2008
Continuation 10954900 · Sep 30, 2004
Division 09920137 · Aug 1, 2001
Provisional Application 60223360 · Aug 7, 2000
Provisional Application 60236826 · Sep 29, 2000
Related Publication 20120282170A1 · Nov 8, 2012